With no head-to-head trial, statisticians built one: tirzepatide edges oral semaglutide

No randomized trial has directly compared injectable tirzepatide against the high-dose oral semaglutide tablet now approved for weight management. A study published this month in Diabetes, Obesity and Metabolism uses a statistical workaround — an indirect comparison method — to estimate how the two would likely compare, by adjusting for differences between the two drugs' separate pivotal trials [s1].

The method, and why it's a workaround rather than a trial

The analysis draws on two existing trials: SURMOUNT-1, which tested tirzepatide through 72 weeks, and OASIS 1, which tested 50 mg daily oral semaglutide through 68 weeks [s1]. Because these were separate trials with somewhat different participant populations, researchers used a technique called multilevel network meta-regression (ML-NMR), which statistically adjusts for known differences between trial populations — in this case, sex, ethnicity, and baseline outcome measures — to produce an estimated comparison [s1]. Both trials enrolled adults without type 2 diabetes who had obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related complication [s1].

This is a real limitation to hold onto throughout: ML-NMR can adjust for measured differences between trial populations, but it cannot account for unmeasured ones, and it remains fundamentally an indirect, model-based comparison rather than a trial where the same people were randomized to one drug or the other under identical conditions.

What it found

Tirzepatide at 10 mg and 15 mg weekly doses were associated with statistically significantly greater weight reduction than oral semaglutide 50 mg daily: a mean difference of −4.48 percentage points (95% CI −6.35 to −2.61) for the 10 mg dose and −5.59 percentage points (95% CI −7.52 to −3.77) for the 15 mg dose [s1]. Waist circumference reduction followed a similar pattern, with tirzepatide producing an additional 3.60 cm (95% CI −5.59 to −1.72) at 10 mg and 4.32 cm (95% CI −6.30 to −2.40) at 15 mg reduction compared with oral semaglutide [s1]. Tirzepatide was also associated with higher odds of participants achieving 5%, 10%, 15%, and 20% weight-loss thresholds [s1]. Cardiometabolic benefits and safety profiles were described as improved or generally comparable between the two drugs [s1].

Reading the numbers

A roughly 4.5-to-5.6-percentage-point gap in weight loss is a meaningful difference at the population level, but it sits on top of the underlying uncertainty inherent to indirect comparisons: different trial durations (72 weeks for tirzepatide's trial versus 68 weeks for oral semaglutide's), different dosing schedules (weekly injection versus daily pill), and different trial-specific factors that adjustment for sex, ethnicity, and baseline measures alone cannot fully resolve. The confidence intervals themselves are fairly wide — the 10 mg tirzepatide estimate spans from about 2.6 to 6.4 percentage points — reflecting that uncertainty.

Why this matters despite the caveats

Oral semaglutide's appeal is convenience — a pill rather than a weekly injection — which could matter to patients who prefer to avoid injections or who have needle aversion, and the drug's own trial (OASIS 1) established its efficacy against placebo independently. This analysis doesn't undermine that; it specifically addresses a different, narrower question — how oral semaglutide is likely to compare with tirzepatide, a comparison no head-to-head trial has yet answered directly, and one that matters increasingly to patients and prescribers choosing between the two.

What this doesn't establish

Indirect comparisons like this one are used across pharmaceutical research precisely because head-to-head trials are expensive and slow, and they can provide genuinely useful estimates — but they are not a substitute for one. Nothing here should be read as equivalent to a randomized trial result. The study doesn't address long-term durability past the trial windows, cost differences between the drugs, or how the comparison might shift with different dose combinations than the ones tested.

What to watch

Whether a company or independent group runs an actual head-to-head randomized trial of tirzepatide against oral semaglutide, which would be the only way to resolve the comparison with the certainty a trial provides. This article is not medical advice.

Sources

1. Indirect Comparative Efficacy and Safety of Tirzepatide Versus Oral Semaglutide for the Treatment of Overweight and Obesity — Diabetes, Obesity and Metabolism, 28 April 2026